Product Categories

Enzalutamide (MDV3100)

Catalog No.S1250
5 5 15 Product Citations

Enzalutamide (MDV3100) is an androgen-receptor (AR) antagonist with IC50 of 36 nM.

Price Stock Quantity  
In DMSO USD 300 In stock
USD 150 In stock
USD 270 In stock
USD 770 In stock
Contact Us
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Selleck USA Tel: +1-832-582-8158[email protected]
Enzalutamide (MDV3100) Chemical Structure

Enzalutamide (MDV3100) Chemical Structure
Molecular Weight: 464.44

Validation & Quality Control

Customer Reviews(3)

Quality Control & MSDS

Related Compound Libraries

Enzalutamide (MDV3100) is available in the following compound libraries:

Inhibitor Library Bioactive Compound Library Cambridge Cancer Compound Library

Androgen Receptor Inhibitors with Unique Features

  • Selective AR Agonist

    Andarine Selective non-steroidal AR agonist, Ki=4 nM.

  • Most Potent AR Antagonist

    ARN-509 Androgen receptor, IC50=16 nM.

  • FDA-approved Antagonist

    Bicalutamide Approved by FDA for prostate cancer.

  • Newest AR Antagonist

    AZD3514 Potent and oral androgen receptor downregulator with Ki of 2.2 μM.

Product Information

  • Compare Androgen Receptor Chemicals
    Compare Androgen Receptor Products
  • Research Area

Product Description

Biological Activity Protocol Clinical Trial Information Chemical Information Customer Reviews Product Citations Tech Support & FAQs

Biological Activity

Description Enzalutamide (MDV3100) is an androgen-receptor (AR) antagonist with IC50 of 36 nM.
Targets Androgen Receptor [1]
IC50 36 nM
In vitro Enzalutamide has greater affinity to AR than Bicalutamide does in a competition assay with 16β-[18F]fluoro-5α-DHT (18-FDHT) in castration-resistant LNCaP/AR cells (AR-overexpressing). While Enzalutamide shows no agonism in LNCaP/AR prostate cells. Enzalutamide antagonizes induction of prostate-specific antigen (PSA) and transmembrane serine protease 2 (TMPRSS2), combination with the synthetic androgen R1881 in parental LNCaP cells. Enzalutamide could inhibit the transcriptional activity of a mutant AR protein (W741C, mutation of Trp741 to Cys). [1] Enzalutamide also prevents nuclear translocation and co-activator recruitment of the ligand-receptor complex. [2]
In vivo Enzalutamide induces great tumor regression in castrate male mice bearing LNCaP/AR xenografts at a dose of 10 mg/kg. [1]
Features

Protocol(Only for Reference)

Kinase Assay: [3]

AR reporter assay Enzalutamide is evaluated by an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells are engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells are also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer. The antagonistic activity of Enzalutamide is tested in the presence of 100 pM of R1881. Engineered LNCaP cells are maintained in Iscove's medium containing 10% fetal bovine serum (FBS). Two days prior to Enzalutamide treatment, the cells are grown in Iscove's medium containing 10% charcoal-stripped FBS (CS-FBS) to deprive of androgens. The cells are split and grown in Iscove's medium containing 10% CS-FBS with 100 pM of R1881 and increasing concentrations of Enzalutamide. After two days of incubation, reporter activities are assayed.

Cell Assay: [1]

Cell lines LNCaP or LNCaP/AR cells
Concentrations 0-10 μM
Incubation Time 1-4 days
Method Enzalutamide is diluted in DMSO. LNCaP or LNCaP/AR cells (104 cells/well) are androgen-starved by growth in media containing 5-10% charcoal-stripped serum for 3-5 days. Then the cells are challenged with various concentrations of Enzalutamide in media containing 5-10% charcoal-stripped serum.

Animal Study: [1]

Animal Models Castration-resistant LNCaP/HR xenografts in male SCID mice
Formulation Formulated in 1% carboxymethyl cellulose, 0.1% Tween-80, 5% DMSO
Dosages 10 mg/kg
Administration Administered via gavage daily
Solubility 0.5% CMC/0.25% Tween 80, 30 mg/mL
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesBaboonDogMonkeyRabbitGuinea pigRatHamsterMouse
Weight (kg)121031.80.40.150.080.02
Body Surface Area (m2)0.60.50.240.150.050.0250.020.007
Km factor202012128653
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Tran C, et al, Science, 2009, 324 (5928), 787-790.

[2] Scher HI, et al, Lancet, 2010, 375(9724), 1437-1446.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2014-01-26)

NCT Number Recruitment Conditions Sponsor
/Collaborators 		Start Date Phases
NCT02278185 Not yet recruiting Adenocarcinoma of the Prostate|Recurrent Prostate Cancer|Stage III Prostate Cancer|Stage IV Prostate Cancer University of Colorado, Denver February 2015 Phase 2
NCT02278185 Not yet recruiting Adenocarcinoma of the Prostate|Recurrent Prostate Cancer|Stage III Prostate Cancer|Stage IV Prostate Cancer University of Colorado, Denver February 2015 Phase 2
NCT02286921 Not yet recruiting Castration Resistant Metastatic Prostate Cancer Sidney Kimmel Comprehensive Cancer Center|Department of D  ...more Sidney Kimmel Comprehensive Cancer Center|Department of Defense January 2015 Phase 2
NCT02288936 Not yet recruiting Hormone-refractory Prostate Cancer Spanish Oncology Genito-Urinary Group January 2015 Phase 2
NCT02339168 Not yet recruiting Prostate Cancer University of California, Davis|National Cancer Institute  ...more University of California, Davis|National Cancer Institute (NCI)|Medivation, Inc.|Astellas Pharma Inc January 2015 Phase 1

view more

Chemical Information

Download Enzalutamide (MDV3100) SDF
Molecular Weight (MW) 464.44
Formula

C21H16F4N4O2S
CAS No. 915087-33-1
Storage 3 years -20℃Powder
6 months-80℃in solvent (DMSO, water, etc.)
Synonyms
Solubility (25°C) * In vitro DMSO 92 mg/mL (198.08 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 0.5% CMC/0.25% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name  4-​[3-​[4-​cyano-​3-​(trifluoromethyl)​phenyl]​-​5,​5-​dimethyl-​4-​oxo-​2-​thioxo-​1-​imidazolidinyl]​-​2-​fluoro-​N-​methyl-benzamide
Molarity Calculator Dilution Calculator Molecular Weight Calculator

Research Area

Customer Reviews (3)


Click to enlarge 		Rating
Source PLoS One 2013 8, e53701. Enzalutamide (MDV3100) purchased from Selleck
Method Western blots/qPCR
Cell Lines CWR-R1 cells
Concentrations 10 μM
Incubation Time 48 h
Results MDV3100 treatment reverses androgen-mediated decreases of Sox2 protein and mRNA in CWR-R1 cells 48 hours after a 24 hour pretreatment with R1881.

Click to enlarge 		Rating
Source PLoS One 2013 8, e53701. Enzalutamide (MDV3100) purchased from Selleck
Method qPCR
Cell Lines prostate cancer cell lines
Concentrations 10 μM
Incubation Time 30 d
Results There is a significant decrease in PSA expression under continuous AR inhibition with MDV3100.

Click to enlarge 		Rating
Source Cancer Sci 2013 104(8), 1027-32. Enzalutamide (MDV3100) purchased from Selleck
Method Transfection and luciferase activity assay
Cell Lines Tramp-C1, PTENCaP8 cells
Concentrations
Incubation Time 48 h
Results When bicalutamide and MDV3100were used to block AR, BMP-6 no longer increased the probasin promoter activity in Tramp-C1 and PTENCaP8 whenRAW 264.7 cells were present.

Product Citations (15)

Customers Who Bought This Item Also Bought

  • ARN-509

    ARN-509 is a selective and competitive androgen receptor inhibitor with IC50 of 16 nM, useful for prostate cancer treatment. Phase 3.

  • Abiraterone

    Abiraterone is a potent CYP17 inhibitor with IC50 of 2 nM.

    Features:Approved for the treatment of docetaxel-treated castration-resistant prostate cancer.

  • Bicalutamide

    Bicalutamide is an androgen receptor (AR) antagonist with IC50 of 0.16 μM.

  • MK-2206 2HCl

    MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

    Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.

  • Abiraterone Acetate

    Abiraterone Acetate is an acetate salt form of Abiraterone which is a steroidal cytochrome CYP17 inhibitor with IC50 of 72 nM.

    Features:Abiraterone is a drug used in castration-resistant prostate cancer.

  • Bortezomib (PS-341)

    Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM.

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions
Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Androgen Receptor Products

  • ARN-509

    ARN-509 is a selective and competitive androgen receptor inhibitor with IC50 of 16 nM, useful for prostate cancer treatment. Phase 3.

  • Bicalutamide

    Bicalutamide is an androgen receptor (AR) antagonist with IC50 of 0.16 μM.

  • Galeterone

    Galeterone is a selective CYP17 inhibitor and androgen receptor (AR) antagonist with IC50 of 300 nM and 384 nM, respectively, and is a potent inhibitor of human prostate tumor growth. Phase 2.

  • Flutamide

    Flutamide is an antiandrogen drug, with its active metablolite binding at androgen receptor with Ki values of 55 nM, and primarily used to treat prostate cancer.

  • Dehydroepiandrosterone (DHEA)

    Dehydroepiandrosterone (DHEA) is a 19-carbon endogenous natural steroid hormone.

  • Andarine

    Andarine is a selective non-steroidal androgen receptor (AR) agonist with Ki of 4 nM, tissue-selective for anabolic organs. Phase 3.

  • MK-2866 (GTx-024)

    MK-2866 (GTx-024) is a selective androgen receptor modulator (SARM) with Ki of 3.8 nM, and is tissue-selective for anabolic organs. Phase 3.

    Features:The most potent and tissue-selective in vivo activity of SARMs to date, with favorable pharmacokinetic properties.

Recently Viewed Items

Tags: buy Enzalutamide (MDV3100) | Enzalutamide (MDV3100) ic50 | Enzalutamide (MDV3100) price | Enzalutamide (MDV3100) cost | Enzalutamide (MDV3100) solubility dmso | Enzalutamide (MDV3100) purchase | Enzalutamide (MDV3100) manufacturer | Enzalutamide (MDV3100) research buy | Enzalutamide (MDV3100) order | Enzalutamide (MDV3100) mouse | Enzalutamide (MDV3100) chemical structure | Enzalutamide (MDV3100) mw | Enzalutamide (MDV3100) molecular weight | Enzalutamide (MDV3100) datasheet | Enzalutamide (MDV3100) supplier | Enzalutamide (MDV3100) in vitro | Enzalutamide (MDV3100) cell line | Enzalutamide (MDV3100) concentration | Enzalutamide (MDV3100) nmr
Contact Us